|1.||Proudfoot, Amanda E I: 5 articles (07/2005 - 07/2002)|
|2.||Teixeira, Mauro Martins: 3 articles (02/2009 - 09/2004)|
|3.||Proudfoot, A E: 3 articles (07/2001 - 03/2000)|
|4.||Soares, Denis M: 2 articles (11/2012 - 08/2007)|
|5.||Souza, Glória E P: 2 articles (11/2012 - 08/2007)|
|6.||Garlet, Gustavo Pompermaier: 2 articles (01/2011 - 04/2010)|
|7.||Avila-Campos, Mario Julio: 2 articles (01/2011 - 04/2010)|
|8.||Silveira, Elcia Maria: 2 articles (01/2011 - 04/2010)|
|9.||Repeke, Carlos Eduardo: 2 articles (01/2011 - 04/2010)|
|10.||Roffê, Ester: 2 articles (08/2010 - 03/2007)|
|1.||Vascular System Injuries
08/01/1999 - "In a renal transplant model (Fisher RT1(lvl) rat kidney into Lewis RT1(l) rat) where no additional immune suppressant was used, Met-RANTES-treated animals showed a significant reduction in vascular injury score (16.10 +/- 5.20 vs. 62.67 +/- 18.64) and tubular damage score (15.70 +/- 5.22 vs. 33.00 +/- 6.44) relative to untreated animals. "
01/01/1999 - "In a renal transplant model (Fisher RT1(1v1) rat kidney into Lewis RT1(1) rat) Met-RANTES-treated animals showed a significant reduction in vascular injury score (16.10 +/- 5.20 vs. 62.67 +/- 18.64) and tubular damage score (15.70 +/- 5.22 vs. 33.00 +/- 6.44) relative to untreated animals. "
06/01/2005 - "Administration of Met-RANTES as a preventative reduced the severity of joint inflammation. "
01/01/2009 - "As receptor trafficking impacts on cell surface expression and the ability of the receptor to respond to more ligand, this information may indicate an alternative regulation of CCR5 by Met-RANTES that allows the modified ligand to reduce inflammation through stimulation of a pro-inflammatory receptor."
03/01/2007 - "However, Met-RANTES treatment of infected mice altered neither parasitism nor intensity and nature of the CNS inflammation, indicating that T. "
08/01/2006 - "If this action is blocked with Met-RANTES, inflammation decreases and viral clearance is delayed. "
06/01/2005 - "Administration of Met-RANTES to ankles with AIA showed decreases in inflammation, radiographic soft tissue swelling, and bone erosion. "
01/01/2009 - "The CCL5 antagonist Met-RANTES reduces diet-induced atherosclerosis; however, CCL5 antagonism may not be therapeutically feasible, as suggested by studies using Ccl5-deficient mice which imply that direct CCL5 blockade would severely compromise systemic immune responses, delay macrophage-mediated viral clearance and impair normal T cell functions. "
02/06/2004 - "In this study, we report that blocking a chemokine pathway in vivo with the CC chemokine antagonist Met-RANTES reduces the progression of atherosclerosis in a hypercholesterolemic mouse model. "
06/01/2005 - "The aim of this study was to investigate whether Met-RANTES could ameliorate adjuvant-induced arthritis (AIA) in the rat. "
10/01/2009 - "In CCR5(-/-) mice and WT mice treated with the CCR5 inhibitor Met-RANTES, exacerbated arthritis developed late in the disease course. "
06/01/2005 - "Met-RANTES significantly reduced the number of neutrophils and macrophages at the peak of arthritis compared with saline-injected controls. "
06/01/2005 - "Amelioration of rat adjuvant-induced arthritis by Met-RANTES."
06/01/1997 - "Furthermore, in MetRANTES-treated mice that did develop arthritis a significantly lower severity of disease was observed compared with control animals. "
|6.||CCR5 Receptors (CCR5 Receptor)
|3.||Transplantation (Transplant Recipients)